Ontruzant, the biosimilar version of Herceptin (trastuzumab) originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK, becoming the first biologic copycat version of Roche’s blockbuster to be available in the region.
Ook interessant voor je
Reageer